DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA) today announces that it has been selected for a Late
Breaking Poster Presentation at the American Diabetes Association's 72nd
Scientific Sessions, June 8-12, 2012 in Philadelphia, PA. The poster titled, "A
Novel Agonist Antibody to the Bradykinin 2 Receptor for the Treatment of Type 2
Diabetes" will be presented on Sunday June 10th and covers results of
pre-clinical studies of DM-204, a novel monoclonal antibody, for the treatment
of Type 2 diabetes. 


"The annual American Diabetes Association is a great forum for us to share the
recent data generated on DM-204 as well as elaborate on its novel mechanism of
action," commented Rick Pauls, Chairman and CEO of DiaMedica. "We are also using
the conference as a platform to begin early stage partnering discussions with
major pharmaceutical and biotechnology companies. These discussions will involve
both DM-204 and DM-199, our recombinant protein for diabetes. We look forward to
a series of productive meetings at the conference."


About DiaMedica

DiaMedica is a biopharmaceutical company focused on discovery and development of
novel therapeutic compounds for diabetes and other major, medically-unmet
diseases. DiaMedica's lead compound, DM-199, is a recombinant human protein that
represents a novel approach to treating Type 1 and Type 2 diabetes. In a Type 1
diabetes model, DM-199 halted the autoimmune attack on beta cells by stimulating
regulatory T-cells, and resulted in a 12-fold increase in C-peptide levels. In
Type 2 diabetes models, DM-199 treatment stimulated proliferation of insulin
producing beta cells, resulting in significant improvement in glucose control.
DiaMedica is also developing a novel monoclonal antibody, DM-204 as a treatment
for Type 2 diabetes. Chronic treatment with DM-204 in a Type 2 diabetes model
resulted in significant improvement in blood glucose control and HbA1c levels
and also significant decreases in blood pressure and serum cholesterol.


Diamedica's DM-199 and DM-204 were both named Windhover's "2011 Top 10
Cardiovascular/ Metabolic Projects to Watch". The Company is listed on the TSX
Venture Exchange under the trading symbol 'DMA'. 


Caution Regarding Forward-Looking Information The statements made in this press
release that are not historical facts contain forward-looking information that
involves risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be considered
forward-looking statements. Such statements are based on management's exercise
of business judgment as well as assumptions made by and information currently
available to management. When used in this document, the words "may", "will",
"anticipate", "believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements. You should not
place undue reliance on these forward-looking statements. These statements
reflect a current view of future events and are subject to certain risks and
uncertainties as contained in the Company's filings with Canadian securities
regulatory authorities. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
could differ materially from those anticipated in these forward-looking
statements. The Company undertakes no obligation, and does not intend, to
update, revise or otherwise publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events. Although
management believes that expectations are based on reasonable assumptions, no
assurance can be given that these expectations will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024